Recent Comments

Comment RSS

Lymphoma News and Research RSS Feed - Lymphoma News and Research

Lymphoma is cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is Hodgkin lymphoma, which is marked by the presence of a type of cell called the Reed-Sternberg cell. The other category is non-Hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-Hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both Hodgkin and non-Hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.

Antigenics to withdraw its MAA for Oncophage following CHMP’s negative opinion

20. November 2009 09:28
Antigenics Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMEA), has formally adopted a negative opinion on the marketing authorization application (MAA) for Oncophage (vitespen) as a treatment in earlier-stage, localized renal cell carcinoma (kidney cancer). [More]

US and European market for radiopharmaceuticals continues to gain momentum

20. November 2009 02:41
Research and Markets (http://www.researchandmarkets.com/research/410c60/radiopharmaceutica) has announced the addition of the "Radiopharmaceuticals - A US and European Market Analysis" report to their offering. [More]

Scientists closer to unraveling the mechanisms of gene regulation

20. November 2009 02:08
A team led by Penn State's Ross Hardison, T. Ming Chu Professor of Biochemistry and Molecular Biology, has taken a large step toward unraveling how regulatory proteins control the production of gene products during development and growth. [More]

Posted in: Medical Science News

Tags: , , , , , , , ,

BioCryst Pharmaceuticals declares proposed public offering of common stock

19. November 2009 23:54
BioCryst Pharmaceuticals, Inc. today announced the pricing of a public offering of 5,000,000 shares of its common stock at $9.75 per share, resulting in gross proceeds of $48.75 million. [More]

Posted in: Business / Finance

Tags: , , ,

Aegera Therapeutics commences AEG35156 Phase 2B study for AML

19. November 2009 10:37
Aegera Therapeutics Inc. announced today the dosing of the first patient in a randomized Phase 2B study of AEG35156, a targeted antisense therapeutic in mid-stage development for multiple oncology indications. [More]

FDA issues complete response for Rituxan, a drug for treating chronic lymphocytic leukemia

19. November 2009 03:13
Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) issued a complete response on the companies’ applications for Rituxan® (rituximab) plus fludarabine and cyclophosphamide (FC) for the treatment of people with previously untreated and previously treated chronic lymphocytic leukemia (CLL). [More]

Millennium commences Phase I clinical trial for its second-generation proteasome inhibitor

18. November 2009 10:31
Millennium: The Takeda Oncology Company today announced it has further expanded its protein homeostasis program with the initiation of a Phase I clinical trial for an oral formulation of MLN9708, the Company’s second-generation proteasome inhibitor. An intravenous formulation of MLN9708 entered clinical trials in March. [More]

Data on Synta Pharmaceuticals' STA-9090 synthetic inhibitor of Hsp90 presented

18. November 2009 08:40
Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that preclinical data presented at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics shows that STA-9090, a novel, synthetic inhibitor of heat shock protein 90 (Hsp90), demonstrated strong activity in multiple tumor models. [More]

BioCryst Pharmaceuticals announces sale of common stock shares

17. November 2009 07:07
BioCryst Pharmaceuticals, Inc. today announced that it is offering to sell, subject to market and other conditions, 5,000,000 shares of its common stock pursuant to an effective shelf registration statement in an underwritten public offering. [More]

Posted in: Business / Finance

Tags: , , ,

New insights into cells' reaction to DNA damage

17. November 2009 04:55
Cancer researchers of the Max Delbr-ck Center for Molecular Medicine (MDC) Berlin-Buch have gained new insights into how cells react to DNA damage. Dr. Michael Stilmann, Dr. Michael Hinz and Professor Claus Scheidereit have shown that the protein PARP-1, which detects DNA damage within seconds, activates the transcription factor NF-kappaB, a well-known regulator of gene expression. [More]

Posted in: Medical Science News

Tags: , , , , , , ,

Seattle Genetics commences phase I clinical trial of SGN-75 ADC for metastatic renal cell carcinoma

16. November 2009 10:40
Seattle Genetics, Inc. today announced that it has initiated a phase I clinical trial of SGN-75 for metastatic renal cell carcinoma and relapsed and refractory non-Hodgkin lymphoma. SGN-75 is an antibody-drug conjugate (ADC) targeting CD70 that utilizes the company’s proprietary technology. [More]

4SC raises funds for further development of its current product pipeline

16. November 2009 10:19
4SC AG, a drug discovery and development company, today announced the successful completion of a capital increase, after the Management Board, with the approval of the Supervisory Board, passed a resolution to authorise an increase of share capital on 23 October, 2009. [More]

Fate Therapeutics announces the completion of $30 million Series B financing

16. November 2009 09:12
Fate Therapeutics, Inc. announced today that it has completed a $30 million Series B financing led by OVP Venture Partners. Joining OVP Venture Partners in the financing is a syndicate of corporate investors, including Astellas Venture Management, Genzyme Ventures and a third undisclosed corporate investor. [More]

Posted in: Business / Finance

Tags: , , , , , , , ,

Pharmacyclics to present clinical updates and posters relating to PCI-24781 and PCI-32765

13. November 2009 05:32
Pharmacyclics, Inc. today announced that posters related to PCI-24781 and PCI-32765 have been selected for presentation at the 51st Annual Meeting of the American Society of Hematology (ASH), December 5-8, 2009 in New Orleans, LA. [More]

Posted in: Pharmaceutical News

Tags: , , , , ,

CMS approves FDG PET for initial staging of cervical cancer

13. November 2009 01:45
SNM applauds the Centers for Medicare & Medicaid Services- (CMS) decision to expand coverage of FDG PET for the initial staging of cervical cancer without previously imposed restrictions. [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.